$77.690
-0.754 (-0.97%)At close
VVX News
VVX Events
V2X Awarded $391M Contract by U.S. Marine Corps
V2X has been awarded a contract with a base value of approximately $391M, with a potential value of up to $500M including all option periods under the contract ceiling, by the U.S. Marine Corps Logistics Command to provide Logistics Integration Support Services for the Marine Force Storage Command's Secondary Repairable program. Under the contract, V2X will coordinate the complex repair and sustainment process for secondary repairable components, helping ensure critical equipment is restored efficiently and returned to service in support of Marine Corps readiness. V2X has supported the Marine Corps' SECREP program for more than twenty years.
Company Reports Q2 Revenue of $1.26B, Beating Expectations
Reports Q2 revenue $1.26B, consensus $1.21B. "With double-digit top and bottom-line growth, our strong second quarter performance reflects consistent strategic execution, robust demand for our differentiated capabilities and continued alignment to national security priorities," said CEO Jeremy Wensinger. "Recent awards across modernization, global training, aerospace and mission readiness reinforce the value of our end-to-end solutions, ability to support global no-fail missions, and pursuit of profitable growth opportunities that increase the value of our backlog. Our solid first-half performance and current backlog position us well as we enter the second half of 2026 and as such are increasing our 2026 outlook for revenue, adjusted EBITDA and adjusted EPS. We remain focused on advancing our Go Towards Tomorrow strategy, prioritizing investments that accelerate innovation across the enterprise and strengthen our competitive solutions, and delivering differentiated value for customers and shareholders."
Raises 2026 Revenue Outlook to $4.875B-$5.025B
Raises 2026 revenue view to $4.875B-$5.025B from $4.825B-$4.975B, consensus $4.93B.
American Industrial Partners Acquires Avanos Medical
American Industrial Partners is acquiring Avanos Medical in a deal expected to close soon, pending final closing conditions.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.








